6:04 PM
 | 
Dec 14, 2012
 |  BC Extra  |  Company News

FDA approves Novartis' Signifor for Cushing's

FDA approved late Friday an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for Signifor pasireotide to treat Cushing's disease when surgery is not an option or has failed. As part of the approval, the pharma...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >